The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...
Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results